Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 20 September, 2013

AstraZeneca PLC

Fluenz Tetra receives positive CHMP opinion in EU

RNS Number : 5425O
AstraZeneca PLC
20 September 2013
 



FLUENZ TETRA, FOUR-STRAIN NASAL SPRAY VACCINE, RECEIVES POSITIVE OPINION IN EU FROM CHMP FOR THE PREVENTION OF SEASONAL INFLUENZA IN CHILDREN

 

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Fluenz Tetra, a nasally administered four-strain live attenuated influenza vaccine, for the prevention of seasonal influenza in eligible children and adolescents 24 months to 17 years of age.

 

Historically, seasonal flu vaccines have contained three strains of influenza: one influenza A (H1N1) virus, one influenza A (H3N2) virus, and one influenza B virus. However, Fluenz Tetra contains two strains of influenza A and two strains of influenza B to provide broad protection against influenza B. Influenza B strains on average account for approximately 25 percent of the influenza strains that circulate in Europe.

 

The positive opinion was reached after a review of data from a pivotal paediatric study.  These data indicated that the safety and immunogenicity profile of Fluenz Tetra was comparable to currently approved three-strain (trivalent) vaccine, Fluenz.  

 

Filip Dubovsky, Vice President of Clinical Biologics Infectious Disease and Vaccines, MedImmune, AstraZeneca's global biologics research and development arm, said: "We are delighted that Fluenz Tetra has received a positive opinion from the CHMP. The inclusion of two influenza B strains in the vaccine will provide broad protection and should help to reduce the overall incidence of influenza."

 

The CHMP's positive opinion on Fluenz Tetra will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Should the EC approve Fluenz Tetra, it will replace Fluenz from the 2014-2015 flu season onwards.

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

CONTACTS

 

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)
Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Tracy Rossin                               +1 301 398 1468      (MedImmune)  

Jacob Lund                                  +46 8 553 260 20  (Sweden)

 

Investor Enquiries

Ed Seage                                    +1 302 886 4065      mob:  +1 302 373 1361

Karl Hård                                     +44 20 7604 8123 mob: +44 7789 654364

Colleen Proctor                           + 1 302 886 1842    mob:  +1 302 357 4882

Anthony Brown                            +44 20 7604 8067   mob: +44 7585 404943

Jens Lindberg                              +44 20 7604 8414   mob: +44 7557 319729

 

20 September 2013

- ENDS -


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFSLAAIIFIV

a d v e r t i s e m e n t